title: Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
abstract: Enzyme replacement is a potential therapy for mucopolysaccharidosis I (MPS I), a lysosomal storage disorder caused by alpha-L-iduronidase deficiency. Previous work showed improvement in the tissues of MPS I dogs treated intravenously for 3 months with recombinant human alpha-L-iduronidase (25,000 units or approximately 0.1 mg/kg/week). We have now treated an MPS I-affected dog for 13 months to assess the clinical effects of enzyme replacement. The treated dog gained more weight, was more active, and had less joint stiffness than the untreated littermate. Biochemical and histologic studies demonstrated uptake of alpha-L-iduronidase and decreased lysosomal storage in the liver, kidney, spleen, lymph nodes, synovium, adrenals, and lungs. The brain had detectable enzyme activity and decreased glycosaminoglycan storage although histologic improvement was not evident. Cartilage and heart valve did not show any detectable improvement. A fivefold higher dose (approximately 0.5 mg/kg) administered five times over 10 days to two other dogs resulted in higher tissue enzyme activity and similarly decreased glycosaminoglycan storage and excretion. Antibodies to human alpha-L-iduronidase were induced in all treated dogs and may be associated with immune complex deposition and proteinuria. Recombinant canine alpha-L-iduronidase also induced antibody formation to a similar degree. The results support the conclusion that enzyme replacement is a promising therapy for MPS I though immunologic complications may occur.
authors.affiliation: Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, California, 90502, USA.
authors.forename: E D
authors.initials: ED
authors.lastname: Kakkis
authors.forename: M F
authors.initials: MF
authors.lastname: McEntee
authors.forename: A
authors.initials: A
authors.lastname: Schmidtchen
authors.forename: E F
authors.initials: EF
authors.lastname: Neufeld
authors.forename: D A
authors.initials: DA
authors.lastname: Ward
authors.forename: R E
authors.initials: RE
authors.lastname: Gompf
authors.forename: S
authors.initials: S
authors.lastname: Kania
authors.forename: C
authors.initials: C
authors.lastname: Bedolla
authors.forename: S L
authors.initials: SL
authors.lastname: Chien
authors.forename: R M
authors.initials: RM
authors.lastname: Shull
mesh_terms: D000818:Animals; D000917:Antibody Formation; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D001923:Brain Chemistry; D002356:Cartilage / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D007068:Iduronidase / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D008247:Lysosomes / Q000378:metabolism / Q000473:pathology; D008297:Male; D008059:Mucopolysaccharidosis I / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D014018:Tissue Distribution
chemical_list: D006025:Glycosaminoglycans; D011994:Recombinant Proteins; D007068:Iduronidase